Lundbeck (HLUN-B.CO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

HLUN-B.CO · Stock Price

DKK 42.98+13.02 (+43.46%)

Market Cap: $6.7B

Historical price data

Market Cap: $6.7BPipeline: 200 drugs (121 Phase 3)Patents: 3Founded: 1915Employees: 5,500-6,000HQ: Copenhagen, Denmark

Sector Ranking#68 in Small Molecule Drugs #4 in Neuroscience & CNS

Overview

Lundbeck is a Danish, publicly-traded biopharmaceutical leader with a century-long legacy, exclusively focused on central nervous system (CNS) disorders. Its strategy as a 'Focused Innovator' leverages deep, accumulated expertise in neuroscience to navigate the complexities of CNS drug development and commercialization. The company has built a significant global commercial footprint, particularly in the U.S., and maintains a robust pipeline aimed at addressing high-unmet-need conditions in psychiatry, neurology, and neuro-rare diseases, underpinned by a strong financial position with a market valuation of approximately $39 billion.

PsychiatryNeurologyNeuro-rare Diseases

Technology Platform

Lundbeck's core platform is its integrated, 70+ year accumulated expertise in neuroscience, encompassing specialized capabilities in CNS drug discovery, blood-brain barrier penetration, neuropharmacology, and clinical development for psychiatric and neurological disorders.

Pipeline

200

200 drugs in pipeline121 in Phase 3

Drug	Indication	Stage
Nalmefene hydrochloride	Alcohol Dependence	Phase 3
Clobazam	Lennox-Gastaut Syndrome	Phase 3
Vortioxetine 10 mg/day + Vortioxetine 20 mg/day + Fluoxetine...	Depressive Disorder, Major	Phase 3
Bifeprunox + Placebo + Quetiapine	Schizophrenia	Phase 3
Brexpiprazole	Schizophrenia	Phase 3

FDA Approved Drugs

6

VYEPTIBLAFeb 21, 2020

NORTHERANDAFeb 18, 2014

ONFINDADec 14, 2012

Opportunities

Significant opportunities exist in the large, underserved markets of migraine prevention and neurodegenerative disease agitation/psychosis, where Lundbeck has advanced candidates.

The strategic focus on neuro-rare diseases offers a high-growth niche with faster development pathways and less commercial competition.

Risk Factors

Key risks include the high failure rate inherent in CNS clinical development, potential revenue erosion from patent expiries on core products, and intense competition and pricing pressure in key therapeutic areas like depression and migraine.

Competitive Landscape

Lundbeck competes with large, diversified pharma in psychiatry and neurology, and with focused biotechs in migraine. Its primary advantage is its pure-play neuroscience focus, which drives deeper expertise and more targeted commercial execution, particularly in the neuro-rare segment it is cultivating.